Affiliation:
1. Department of Cardiac Surgery, Medical University of Vienna, Vienna, Austria
2. Center for Medical Statistics, Informatics and Intelligent Systems, Medical University of Vienna, Vienna, Austria
Abstract
Abstract
OBJECTIVES
Long-term durability of surgical bio-prostheses is a key factor, especially in the era of transcatheter aortic valve replacement. We compared the incidence of structural valve deterioration (SVD) between patients undergoing surgical aortic valve replacement (SAVR) with the Trifecta (Abbott Laboratories, Abbott Park, IL, USA) or the Intuity valve (Edwards Lifesciences, Irvine, CA, USA).
METHODS
Between April 2010 and May 2020, 1118 patients underwent SAVR with the Trifecta (n = 346) and the Intuity (n = 772) valve at a single centre. A total of 1070 patients (Trifecta n = 298, Intuity n = 772) were analysed after the exclusion of patients with pure regurgitation and endocarditis. Retro- and prospective echocardiographic and clinical follow-up was performed. Cox proportional hazards regression models were performed to identify prognostic factors for SVD, aortic re-interventions and mortality.
RESULTS
With 27 cases (Trifecta n = 23, Intuity n = 4) of SVD observed, cumulative incidence of SVD was significantly higher in the Trifecta cohort (P < 0.001). Implantation of a Trifecta valve [hazard ratio (HR) 11.20; 95% confidence interval 3.79–33.09], log-transformed preoperative creatinine (HR 2.47; 1.37–4.44) and sex (male HR 0.42; 0.19–0.92) emerged as prognostic factors of SVD. A significantly higher cumulative incidence of re-interventions was observed in the Trifecta cohort (P = 0.004) and valve type was an independent time-varying risk factor (HR at 12 months 2.78; 95% confidence interval 1.42–5.45). Overall, no significant differences in all-cause mortality were observed between the groups (log-rank test: P = 0.052).
CONCLUSIONS
SVD was significantly more frequent in patients receiving a Trifecta valve and its implantation was an independent risk factor for the occurrence of SVD and aortic valve re-interventions. This comparative analysis of 2 low-gradient bioprosthesis put the long-term durability of the Trifecta valve in question and need to be taken into consideration when performing bioprosthetic SAVR.
Funder
Edwards Lifesciences (Edwards Lifesciences
Publisher
Oxford University Press (OUP)
Subject
Cardiology and Cardiovascular Medicine,Pulmonary and Respiratory Medicine,General Medicine,Surgery
Reference27 articles.
1. Contemporary real-world outcomes of surgical aortic valve replacement in 141,905 low-risk, intermediate-risk, and high-risk patients;Thourani;Ann Thorac Surg,2015
2. Midterm, multicenter clinical and hemodynamic results for the Trifecta aortic pericardial valve;Goldman;J Thorac Cardiovasc Surg,2017
3. Mid-term durability of the Trifecta bioprosthesis for aortic valve replacement;Anselmi;J Thorac Cardiovasc Surg,2017
4. Trifecta aortic bioprosthesis: midterm results in 1,953 patients from a single center;Kilic;Ann Thorac Surg,2019
5. Long-term outcomes of a rapid deployment aortic valve: data up to 5 years;Laufer;Eur J Cardiothorac Surg,2017
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献